Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 451 to 475 of 2013

TitleReference numberPublishedLast updated
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Endoluminal gastroplication for gastro-oesophageal reflux diseaseHTG661
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionHTG662
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Regorafenib for previously treated metastatic colorectal cancerTA866
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Transvenous obliteration for gastric varicesHTG658
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Trabeculectomy with a biodegradable collagen matrix implant for glaucomaHTG656
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
MRI-based technologies for assessing non-alcoholic fatty liver diseaseHTG655

Results per page

  1. 10
  2. 25
  3. 50
  4. All